volume 32 number 4 april 2014 (Nature Biotechnology)
90
Structured Review
Nature Biotechnology
volume 32 number 4 april 2014
Volume 32 Number 4 April 2014, supplied by Nature Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/volume+32+number+4+april+2014/volume+35+number+4+april+2017/pm24714477-0-4-6
Average 90 stars, based on 1 article reviews
Volume 32 Number 4 April 2014, supplied by Nature Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/volume+32+number+4+april+2014/volume+35+number+4+april+2017/pm24714477-0-4-6
Average 90 stars, based on 1 article reviews
volume 32 number 4 april 2014 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
CRISPR:Article Title: Immune-checkpoint inhibitors march on, now in combinations. Article Snippet: study suggests that inhibition of extracellular signal–regulated kinase (ERK) may overcome combined resistance to BRAF and MEK inhibition (Cancer Res.. 4, 61–68, 2013).. Another suggests that inhibiting autophagy, a cell survival mechanism induced in response to stress, with the anti-malaria drug hydroxycholoroquine can achieve a similar outcome (J. Clin. Article Title: A survey of breakthrough therapy designations. Article Snippet: 323 and review (FDA must respond within 60 days of request).. Accelerated approval (generally applied when a sponsor is moving toward confirmatory trials) is for drugs that show meaningful benefit over existing therapies and provides an FDA approval based not on a clinical end point but on an effect or surrogate or intermediate end point that is reasonably likely to predict a drug’s clinical benefit.. A last path, priority review (associated with a biologic license application, new drug application or supplemental application)—which is for drugs providing significant improvement of safety or effectiveness or requiring a labeling change under a pediatric indication or with a QIDP designation or accompanied by a priority review voucher—provides shorter review of a sponsor’s marketing application (6 months rather than the standard 10-month review). Article Title: Gene editing at CRISPR speed. Article Snippet: The inner workings CRISPR-Cas creates double-stranded cuts in DNA, triggering DNA repair mechanisms that can knock out a gene by breaking its sequence or, more rarely, tweak a gene by inserting an alternative DNA sequence from another template.. It is not the only gene-editing technology that works this way.. ZFNs, described first in 1996 (ref. 11) combine the DNA-cutting domain of a bacterial restriction enzyme with DNA-recognition elements; TALENs, reported in 2009, are also fusions (the same DNAcutting domain combined with modular DNA recognition elements found in plant pathogens12,13). Article Title: Putting cells to sleep for future science. Article Snippet: volume 32 NumBeR 4 Fluorescence:Article Title: Immune-checkpoint inhibitors march on, now in combinations. Article Snippet: study suggests that inhibition of extracellular signal–regulated kinase (ERK) may overcome combined resistance to BRAF and MEK inhibition (Cancer Res.. 4, 61–68, 2013).. Another suggests that inhibiting autophagy, a cell survival mechanism induced in response to stress, with the anti-malaria drug hydroxycholoroquine can achieve a similar outcome (J. Clin. Article Title: A survey of breakthrough therapy designations. Article Snippet: 323 and review (FDA must respond within 60 days of request).. Accelerated approval (generally applied when a sponsor is moving toward confirmatory trials) is for drugs that show meaningful benefit over existing therapies and provides an FDA approval based not on a clinical end point but on an effect or surrogate or intermediate end point that is reasonably likely to predict a drug’s clinical benefit.. A last path, priority review (associated with a biologic license application, new drug application or supplemental application)—which is for drugs providing significant improvement of safety or effectiveness or requiring a labeling change under a pediatric indication or with a QIDP designation or accompanied by a priority review voucher—provides shorter review of a sponsor’s marketing application (6 months rather than the standard 10-month review). Article Title: Gene editing at CRISPR speed. Article Snippet: The inner workings CRISPR-Cas creates double-stranded cuts in DNA, triggering DNA repair mechanisms that can knock out a gene by breaking its sequence or, more rarely, tweak a gene by inserting an alternative DNA sequence from another template.. It is not the only gene-editing technology that works this way.. ZFNs, described first in 1996 (ref. 11) combine the DNA-cutting domain of a bacterial restriction enzyme with DNA-recognition elements; TALENs, reported in 2009, are also fusions (the same DNAcutting domain combined with modular DNA recognition elements found in plant pathogens12,13). Article Title: Putting cells to sleep for future science. Article Snippet: volume 32 NumBeR 4 In Situ Hybridization:Article Title: Immune-checkpoint inhibitors march on, now in combinations. Article Snippet: study suggests that inhibition of extracellular signal–regulated kinase (ERK) may overcome combined resistance to BRAF and MEK inhibition (Cancer Res.. 4, 61–68, 2013).. Another suggests that inhibiting autophagy, a cell survival mechanism induced in response to stress, with the anti-malaria drug hydroxycholoroquine can achieve a similar outcome (J. Clin. Article Title: A survey of breakthrough therapy designations. Article Snippet: 323 and review (FDA must respond within 60 days of request).. Accelerated approval (generally applied when a sponsor is moving toward confirmatory trials) is for drugs that show meaningful benefit over existing therapies and provides an FDA approval based not on a clinical end point but on an effect or surrogate or intermediate end point that is reasonably likely to predict a drug’s clinical benefit.. A last path, priority review (associated with a biologic license application, new drug application or supplemental application)—which is for drugs providing significant improvement of safety or effectiveness or requiring a labeling change under a pediatric indication or with a QIDP designation or accompanied by a priority review voucher—provides shorter review of a sponsor’s marketing application (6 months rather than the standard 10-month review). Article Title: Gene editing at CRISPR speed. Article Snippet: The inner workings CRISPR-Cas creates double-stranded cuts in DNA, triggering DNA repair mechanisms that can knock out a gene by breaking its sequence or, more rarely, tweak a gene by inserting an alternative DNA sequence from another template.. It is not the only gene-editing technology that works this way.. ZFNs, described first in 1996 (ref. 11) combine the DNA-cutting domain of a bacterial restriction enzyme with DNA-recognition elements; TALENs, reported in 2009, are also fusions (the same DNAcutting domain combined with modular DNA recognition elements found in plant pathogens12,13). Article Title: Putting cells to sleep for future science. Article Snippet: volume 32 NumBeR 4 In Situ:Article Title: Immune-checkpoint inhibitors march on, now in combinations. Article Snippet: study suggests that inhibition of extracellular signal–regulated kinase (ERK) may overcome combined resistance to BRAF and MEK inhibition (Cancer Res.. 4, 61–68, 2013).. Another suggests that inhibiting autophagy, a cell survival mechanism induced in response to stress, with the anti-malaria drug hydroxycholoroquine can achieve a similar outcome (J. Clin. Article Title: A survey of breakthrough therapy designations. Article Snippet: 323 and review (FDA must respond within 60 days of request).. Accelerated approval (generally applied when a sponsor is moving toward confirmatory trials) is for drugs that show meaningful benefit over existing therapies and provides an FDA approval based not on a clinical end point but on an effect or surrogate or intermediate end point that is reasonably likely to predict a drug’s clinical benefit.. A last path, priority review (associated with a biologic license application, new drug application or supplemental application)—which is for drugs providing significant improvement of safety or effectiveness or requiring a labeling change under a pediatric indication or with a QIDP designation or accompanied by a priority review voucher—provides shorter review of a sponsor’s marketing application (6 months rather than the standard 10-month review). Article Title: Gene editing at CRISPR speed. Article Snippet: The inner workings CRISPR-Cas creates double-stranded cuts in DNA, triggering DNA repair mechanisms that can knock out a gene by breaking its sequence or, more rarely, tweak a gene by inserting an alternative DNA sequence from another template.. It is not the only gene-editing technology that works this way.. ZFNs, described first in 1996 (ref. 11) combine the DNA-cutting domain of a bacterial restriction enzyme with DNA-recognition elements; TALENs, reported in 2009, are also fusions (the same DNAcutting domain combined with modular DNA recognition elements found in plant pathogens12,13). Article Title: Putting cells to sleep for future science. Article Snippet: volume 32 NumBeR 4 |